Loxo Oncology (LOXO +1.9%) inks a collaboration agreement with Roche's Ventana Medical Systems aimed at developing and commercializing a pan-TRK immunohistochemistry (IHC) test as a companion diagnostic to identify suitable patients for treatment with Loxo's lead product candidate larotrectinib (LOXO-101).
The companies will work with an investigational assay piloted by Loxo that will be further developed by Roche using its OptiView DAB detection technology. Roche will be responsible for obtaining regulatory approvals in the U.S. and countries that recognize the CE Mark. Financial terms are not disclosed.
LOXO-101 inhibits a group of enzymes called tropomyosin receptor kinases (TRK), a group of proteins that play a key role in cellular communications. Cancers hijack these communication pathways to send messages to the cells to grow, change or survive. Those characterized by these alterations, termed NTRK fusions, are the therapeutic targets for LOXO-101.